Although the chronic treatment of diabetic patients with the PPARγ agonist pioglitazone reduces dementia risk by 47% [184], Takeda and U.S. partner Zinfandel Pharmaceuticals decided to give up and stop testing a 20-year-old diabetes medicine that fails once more in AD therapy, a lack of success attributed to the low penetrance of glitazones in the brain. The gene discussed is PPARG; the disease is Alzheimer disease.